Introduction
Healthcare decisions within the National Health Service are made within several overlapping systems of authority. Statute and regulations establish legal powers and duties; courts define and interpret legal rights and limits; professional regulators establish standards governing clinicians; the National Institute for Health and Care Excellence (NICE) evaluates evidence and issues recommendations; NHS commissioners determine the availability and funding of services; individual organisations maintain formularies, referral criteria and local policies; and clinicians remain responsible for applying professional judgement to the circumstances of individual patients. These layers interact, but they are not legally equivalent.
This distinction is particularly important when a patient is told that a treatment “cannot” be provided. Such a statement may describe a legal prohibition, a restriction on a particular practitioner's competence, a requirement for specialist initiation, an evidence-based clinical judgment, a NICE recommendation, a commissioning decision, a local formulary rule, an organisational policy, or simply established practice. Each carries a different legal and professional meaning and may provide a different route for reconsideration, referral, exception, funding or review.
This paper examines the consequences of failing to distinguish those categories. Its central proposition is not that patients possess a general legal entitlement to demand any treatment they prefer, nor that clinicians may disregard legitimate NHS resource constraints. Existing authority supports neither proposition. Rather, the paper asks whether healthcare decisions can be made safer and more transparent by requiring the basis of a restriction to be identified accurately, tested against the relevant hierarchy of law and professional obligation, and applied to the circumstances of the individual patient before an alternative treatment pathway is closed.
The problem is not new. Whiteman's analysis of The Fallacy of Choice in the Common Law and NHS Policy examined the gap between the rhetoric of patient choice and the more limited choices recognised by English law and NHS policy (Whiteman, 2013). Sheppard subsequently argued that patient choice may nevertheless have a wider institutional function, operating not only as an expression of individual autonomy but also as a mechanism capable of encouraging changes in healthcare practice and organisation (Sheppard, 2016). Cave's analysis of shared decision-making further clarifies the boundary between professional and patient autonomy: healthcare professionals retain responsibility for identifying clinically reasonable treatment options, while the informed patient has an increasingly important role in choosing between those options (Cave, 2020).
The case law reflects the same balance. Montgomery v Lanarkshire Health Board [2015] UKSC 11 established a patient-centred approach to information about material risks and reasonable alternatives. More recently, McCulloch v Forth Valley Health Board [2023] UKSC 26 confirmed that determining whether an alternative is clinically reasonable still involves professional clinical judgment. Patient autonomy therefore does not create a right to compel the provision of every proposed intervention; equally, professional judgment does not remove the requirement for meaningful patient involvement, adequate information and consideration of reasonable alternatives.
Resource allocation introduces another layer. In R (Rogers) v Swindon NHS Primary Care Trust [2006] EWCA Civ 392, the Court of Appeal demonstrated that an NHS funding policy may be susceptible to judicial review where distinctions made within it cannot rationally be justified. Conversely, R (Condliff) v North Staffordshire Primary Care Trust [2011] EWCA Civ 910 demonstrates that restrictive NHS funding criteria are not inherently unlawful merely because they prevent an individual from receiving treatment. Together these authorities establish an important principle for the present study: NHS organisations may ration and prioritise finite resources, but the existence of a policy does not place that policy beyond legal examination.
This legal question increasingly intersects with the relationship between publicly funded care and private healthcare. Guy's analysis of the boundary between “going private” and “NHS privatisation” identified distinct but interconnected legal and policy frameworks governing NHS patient choice and movement between NHS and private provision (Guy, 2019). More recent work by Guy and Newcombe maps the continuing role of the private healthcare market in supporting NHS patient-choice policy and demonstrates how closely NHS access arrangements now interact with independent-sector capacity (Guy and Newcombe, 2025). This literature is important because treatment availability is no longer adequately understood solely through the traditional patient–doctor relationship. Decisions may also involve commissioners, Integrated Care Boards, provider organisations, private contractors, formularies, funding mechanisms and information-governance systems.
The distinction becomes particularly visible where a treatment is legally capable of being prescribed but access through the NHS remains restricted. NHS England's 2019 review of barriers to cannabis-based medicinal products provides an unusually clear institutional example. Following the 2018 legal rescheduling of certain cannabis-based products for medicinal use, NHS England examined why lawful prescribing did not necessarily translate into patient access. Its review considered barriers arising at several points in the healthcare system, including clinical evidence, professional confidence, organisational governance, pharmacy arrangements and commissioning. The review illustrates a central proposition of this paper: legal possibility, clinical appropriateness, professional competence, organisational approval and NHS funding are separate questions and should not be represented as though they were one decision (NHS England and NHS Improvement, 2019).
This separation also has implications for patient safety. Where standard treatment has failed, produced significant adverse effects or is unacceptable to an informed patient, simply closing an alternative pathway does not necessarily end the underlying clinical problem. The patient may remain in pain or otherwise untreated. Possible subsequent pathways include continued NHS care, specialist reassessment, private treatment, self-treatment, online purchasing, illicit supply, or no treatment at all. These outcomes carry markedly different levels of clinical monitoring, pharmaceutical quality control, financial exposure and diagnostic oversight.
The paper therefore introduces the concept of care displacement: the possibility that barriers within one part of a healthcare system alter where and how a patient subsequently seeks treatment. Care displacement should not be confused with legal causation. The fact that a patient later purchases private treatment or self-medicates does not, without further evidence, establish that an NHS organisation legally caused that conduct or intended the outcome. It does, however, justify examination of whether such displacement was reasonably foreseeable, whether its associated risks were considered when access policy was developed, and whether safer alternative pathways were available.
A related concern is the potential effect of commercial interests. The existence of private providers, contractual relationships or private treatment alternatives does not itself demonstrate an improper financial motive. This paper therefore treats financial influence as an evidential question rather than a presumption. Where a public treatment pathway is restricted while an equivalent or related private pathway remains available, appropriate questions include who made the restriction, under what authority, whether individual exceptions exist, which organisations subsequently receive patients or funds, what conflicts of interest have been declared, and whether patients have been accurately informed about the distinction between legal prohibition and NHS policy.
For the purposes of this study, the term misrepresentation of legal standing is used cautiously. It does not necessarily imply fraud, deliberate deception or professional misconduct. It describes circumstances in which a rule of lesser authority — for example, a commissioning decision, local policy, formulary restriction or customary practice — is communicated or applied as though it constituted a legal prohibition, where the underlying legal position is materially different. Whether any particular instance is innocent error, inadequate training, institutional culture, defensive practice, administrative simplification or deliberate misrepresentation must be determined from evidence.
The paper consequently adopts an evidence-audit approach. Decisions are classified by source and authority before their merits are assessed. The relevant question is not simply whether treatment was provided or refused, but why. A decision may be clinical, legal, professional, evidential, financial, commissioning-based, administrative or organisational. Once its basis has been identified, it becomes possible to test whether the correct decision-maker acted within lawful powers, whether relevant patient circumstances were considered, whether professional discretion was preserved, whether alternatives or referral routes existed, and whether the reasoning was properly recorded.
This analysis is translated into four supporting practical instruments:
Tool 1 — Doctor Legal Abilities and Duties identifies the clinician's legal and professional powers, limitations and responsibilities, including competence, prescribing, referral, monitoring, informed decision-making and the duty to raise concerns where organisational systems or policies jeopardise patient care.
Tool 2 — NHS Policy versus Law Assessment provides a structured method for determining whether a restriction arises from legislation, regulation, NICE guidance, commissioning, formulary rules, organisational policy or local practice, and for identifying the authority, exceptions and review mechanisms associated with that restriction.
Tool 3 — Patient Legal Standing Against NHS Policy identifies the patient's enforceable rights and legitimate procedural expectations while recognising the legal limits of patient demand. Its purpose is to support informed participation, reasonable alternatives, explanation, reconsideration, reasonable adjustments, referral and lawful challenge rather than to create an artificial entitlement to a particular intervention.
Tool 4 — GP Obstruction, Treatment Access and Medication Safety applies those principles prospectively to patient safety. It is designed to identify previous medication harms, clarify the reason for proposed treatment, distinguish an inability to prescribe from an inability to refer, identify appropriate specialist or funding pathways, and ensure that refusal of one option does not inadvertently become the end of clinical care.
Taken together, these tools form a Patient–Clinician Decision Audit. The model is intended to be non-adversarial. Its first objective is not complaint, litigation or professional sanction, but verification. Where uncertainty concerns clinical safety, a pharmacist, second clinician or relevant specialist may provide independent assessment. Where uncertainty concerns professional obligations, published General Medical Council standards or an anonymised standards enquiry may clarify the applicable duties. Medicines regulation, NICE guidance, commissioning rules, equality obligations and data governance can likewise be verified through the body responsible for the relevant domain. Formal complaints, regulatory action and litigation remain available where justified, but are positioned later in the process rather than being the mechanism by which ordinary uncertainty is first resolved.
The framework therefore seeks to protect clinicians as well as patients. A doctor confronted with an unusual treatment request should not be placed in the position of choosing between unquestioning compliance with organisational policy and unsupported departure from normal practice. A structured process provides a third route: identify the governing rule, establish the clinical evidence, determine competence, obtain specialist advice where appropriate, document the patient's individual circumstances and preferences, verify uncertainties, and provide a reasoned decision. Where organisational policy itself may compromise patient safety or care, the doctor's independent professional obligations remain relevant.
This paper does not argue for the removal of clinical judgment, commissioning or evidence-based standards. It argues for accurate classification and transparent application of each. Nor does it assume that NHS restrictions are inherently abusive or that private healthcare involvement is inherently improper. Instead, it provides a framework through which those propositions can be investigated rather than presumed.
The broader literature has already identified the tension between patient choice and professional autonomy, between individual need and collective resource allocation, and between public healthcare and private provision. The contribution proposed here is to bring those strands together into an integrated legal-clinical process capable of being used at the point where an actual healthcare decision is being made.
The ultimate question is therefore not simply:
“Can the patient have the treatment they request?”
It is:
“What prevents the treatment from being considered or provided; what authority creates that restriction; has the patient's individual clinical position been properly assessed; what lawful and clinically appropriate alternatives remain available; and how can those conclusions be independently verified before avoidable harm occurs?”
That question provides the organising principle for the analysis and tools that follow.
References cited in this introduction
Cave, E. (2020) ‘Selecting Treatment Options and Choosing Between Them: Delineating Patient and Professional Autonomy in Shared Decision-Making’, Health Care Analysis, 28, pp. 4–24. DOI: 10.1007/s10728-019-00384-8.
Guy, M. (2019) ‘Between “going private” and “NHS privatisation”: patient choice, competition reforms and the relationship between the NHS and private healthcare in England’, Legal Studies, 39(3), pp. 479–498. DOI: 10.1017/lst.2018.55.
Guy, M. and Newcombe, L. (2025) ‘NHS Patient Choice Policy in England: What Mapping the Private Healthcare Market for NHS Patients Can Tell Us’, Liverpool Law Review, 46, pp. 357–383. DOI: 10.1007/s10991-025-09395-z.
NHS England and NHS Improvement (2019) Barriers to accessing cannabis-based products for medicinal use on NHS prescription. London: NHS England and NHS Improvement.
Sheppard, M.K. (2016) ‘Fallacy or Functionality: Law and Policy of Patient Treatment Choice in the NHS’, Health Care Analysis, 24(4), pp. 279–300. DOI: 10.1007/s10728-014-0275-6.
Whiteman, I. (2013) ‘The Fallacy of Choice in the Common Law and NHS Policy’, Health Care Analysis, 21(2), pp. 146–170. DOI: 10.1007/s10728-011-0198-4.
Cases
McCulloch and others v Forth Valley Health Board [2023] UKSC 26.
Montgomery v Lanarkshire Health Board [2015] UKSC 11.
R (Condliff) v North Staffordshire Primary Care Trust [2011] EWCA Civ 910.
R (Rogers) v Swindon NHS Primary Care Trust [2006] EWCA Civ 392.